Publications, Pharmaceutical

Aptar Pharma discusses an antibody nasal spray for SARS-CoV-2

The delivery of antibodies by nasal spray has considerable potential for the treatment of SARS-CoV-2 and other viruses that enter the body via the upper respiratory system.

This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.

Download Publication
8 Dec 2021

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

1 Jun 2018

Connected Medicine: Insights from Payers and Other Stakeholders

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 Apr 2018

A track record of success for nasal drug delivery in drug repurposing

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
16 Sep 2016

The Nasal Drug Delivery Journey: from Systemic to Nose-to-Brain?

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations

Read More
3 Jun 2015

Using multi-dose nasal spray pumps for intranasal drug delivery

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 23 24 25
Back To Top